Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Avalo Therapeutics, Inc. (AVTX) had Normalized Pre-Tax Income of $-36.34M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-36.36M |
|
-- |
|
-- |
|
$31.52M |
|
$-31.52M |
|
$-4.82M |
|
$-36.34M |
|
|
Normalized Pre-Tax Income |
$-36.34M |
$-36.36M |
|
$-36.36M |
|
$-36.36M |
|
$-36.36M |
|
$-31.52M |
|
$-31.50M |
|
43.60M |
|
43.60M |
|
$-0.83 |
|
$-0.83 |
|
| Balance Sheet Financials | |
$407.93M |
|
$0.29M |
|
$82.85M |
|
$490.78M |
|
$21.13M |
|
-- |
|
$20.99M |
|
$42.12M |
|
$448.66M |
|
$438.16M |
|
$448.66M |
|
52.90M |
|
| Cash Flow Statement Financials | |
$-37.68M |
|
$-304.42M |
|
$411.61M |
|
$16.11M |
|
$85.61M |
|
$69.51M |
|
$8.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.68M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.10% |
|
-8.30% |
|
-7.41% |
|
-8.10% |
|
$8.48 |
|
$-0.86 |
|
$-0.86 |
|